Evidence map›Paper›PMID 38030304›Full record

ArticleJournal for immunotherapy of cancer2023

TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.

Jiongjie Yu, Sunbin Ling, Jiachen Hong, Lincheng Zhang, Wei Zhou, Lu Yin, Shengjun Xu, Qingyang Que, Yongfeng Wu, Qifan Zhan and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. The role of PD‑1/PD‑L1 axis in liver diseases.Clinical and experimental medicine · 2025
    Review
  17. Article
  18. Article
  19. [Novel research horizon for liver transplantation management model in hepatocellular carcinoma based on the tumor-donor liver-recipient].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 3 countries.

Jiongjie YuZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Sunbin LingZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jiachen HongHangzhou Normal University, Hangzhou, China.
Lincheng ZhangZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Wei ZhouZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Lu YinKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, China.
Shengjun XuZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Qingyang QueZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yongfeng WuKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, China.
Qifan ZhanZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jiaqi BaoZhejiang Chinese Medical University, Hangzhou, China.
Nan XuZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yuchen LiuCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou, China.
Kangchen ChenZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xuyong WeiZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zhikun LiuZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Tingting FengDepartment of Colorectal Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Lin ZhouNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Haiyang XieNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Shuai WangZhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jimin LiuDepartment of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Shusen ZhengNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.
Xiao XuZhejiang University School of Medicine, Hangzhou, Zhejiang, China zjxu@zju.edu.cn.ORCID 0000-0002-2761-2811
Integrated Oncology (United States) · USFirst Affiliated Hospital Zhejiang University · CNZhejiang Chinese Medical University · CNZhejiang University · CNHangzhou Normal University · CNMcMaster University · CAZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunotherapy has facilitated great breakthroughs in the treatment of hepatocellular carcinoma (HCC). However, the efficacy and response rate of immunotherapy are limited and vary among different patients with HCC. TP53 mutation substantially affects the expression of immune checkpoint molecules in multiple cancers. However, the regulatory relationship between programmed death ligand 1 (PD-L1) and TP53 is poorly studied in HCC. We aimed to elucidate the regulatory mechanism of PD-L1 in HCC with different TP53 statuses and to assess its role in modulating immune evasion in HCC.

methodsHCC mouse models and cell lines with different TP53 statuses were constructed. PD-L1 levels were detected by PCR, western blotting and flow cytometry. RNA-seqencing, immunoprecipitation, chromatin immunoprecipitation and transmission electron microscopy were used to elucidate the regulatory mechanism in HCC with different TP53 status. HCC mouse models and patient with HCC samples were analyzed to demonstrate the preclinical and clinical significance of the findings.

resultsWe report that loss of p53 promoted PD-L1 expression and reduced CD8

conclusionWe revealed the bidirectional regulatory mechanism of PD-L1 mediated by TP53/mTORC1 in HCC. The combination of mTOR inhibitor and anti-PD-L1 antibody could be a novel precise immunotherapy scheme for TP53 wild-type HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsB7-H1 AntigenHumansImmune EvasionMammalsMechanistic Target of Rapamycin Complex 1MiceTOR Serine-Threonine KinasesTumor Suppressor Protein p53B7-H1 AntigenCD274 protein, humanMechanistic Target of Rapamycin Complex 1TOR Serine-Threonine KinasesTP53 protein, humanTumor Suppressor Protein p53CD8-Positive T-LymphocytesImmune Checkpoint InhibitorsImmunotherapyLiver NeoplasmsTumor Microenvironment

Identifiers

PMID38030304
PMCPMC10689408
OpenAlexW4389130677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.